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RNA interferencen restraining tumor progression by more than one mechanism, involving both its
catalytic and transcriptional co-repressor functions. Starting from the ﬁnding that HIPK2 knockdown by
RNA-interference (HIPK2i) induced signiﬁcant up-regulation of HIF-1αmRNA and of its target VEGF in tumor
cells, we evaluated the role of HIPK2 in transcriptional regulation of HIF-1α. We found that HIPK2
overexpression downmodulated both HIF-1α reporter activity and mRNA levels and showed that HIPK2 was
bound in vivo to the HIF-1α promoter likely in a multiprotein co-repressor complex with histone deacetylase
1 (HDAC1). Thus, the HIF-1α promoter was strongly acetylated following HIPK2 knockdown. The HIF-1α-
dependent VEGF transcription was evaluated by co-transfection of a dominant negative (DN) construct of
HIF-1α that inhibited VEGF reporter activity induced by HIPK2 knockdown. HIF-1α and VEGF up-regulation
in HIPK2i cells correlated with increased vascularity of tumor xenografts in vivo and tube formation in
HUVEC in vitro. These ﬁndings provide the ﬁrst evidence of HIPK2-mediated transcriptional regulation of
HIF-1α that might play a critical role in VEGF expression.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Homeodomain-interacting protein kinase-2 (HIPK2) is a serine/
threonine kinase that belongs to a family of corepressors for home-
odomain transcription factors [1] that regulates gene expression by
phosphorylation of transcription factors and several different compo-
nents of the transcription machinery. HIPK2 binds, in multiprotein
complex, to other co-repressors such as Groucho and histone
deacetylase 1 (HDAC1) [2] and its role as transcriptional regulator
has been demonstrated for several different transcription factors
including Smad1/4, CtBP, and Brn3a [3–5], regulating cell survival and
apoptosis. We have recently found that HIPK2, along with histone
deacetylase 1 (HDAC1), co-represses cytosolic-phospholipase A2
(cPLA2) promoter activity; thus, HIPK2 knockdown induces cPLA2
up-regulation and cPLA2-dependent prostaglandin E2 (PGE2) bio-
synthesis correlated to tumor progression [6]. The kinase activity oful Cancro (AIRC) and Ministero
and Neurosciences, N.P.D.,
13 Chieti, Italy. Tel.: +39 06
D'Orazi).
l rights reserved.HIPK2 is often required for transcription factor regulation, including
phosphorylation and degradation of co-repressors such as CtBP or c-
Myb [4,7]. One notable target of HIPK2 is p53 [8,9]. In response to
severe DNA damage HIPK2 binds to and phosphorylates p53 inducing
p53-dependent apoptotic target gene transcription. Moreover, the
HIPK2-activated p53 represses at transcriptional level the antiapop-
totic Galectin-3 protein [10]. Combined, HIPK2 can regulate cell
growth by binding to or phosphorylating various transcription factors
and cofactors to regulate either positively or negatively their
transcriptional activity. HIPK2 is often inactivated in tumors by
multiple mechanisms such as downregulation, mutation, and mis-
localization [6,11–14], therefore, it is important to have a wider
understanding of the regulation of HIPK2-dependent pathways that
control tumor progression.
The tumor progression is often dictated by increased vascularity
following vascular endothelial growth factor (VEGF) up-regulation
[15]. A large array of oncoproteins overactive in cancer cells acts as
VEGF inducers, creating a challenge in tumor therapy for blocking
VEGF production and starve tumors [16]. Thus, due to its role in tumor
angiogenesis VEGF is overexpressed in a wide variety of human
cancers [17,18]. The major transcription factor that has been found for
VEGF expression is hypoxia inducible factor-1 (HIF-1), a heterodimeric
transcription factor that consists of two subunits, HIF-1α and HIF-1β
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is stimulated by hypoxia, growth factors, and several oncogenes [20].
After dimerizationwith HIF-1β, HIF-1α binds to a consensus sequence
called hypoxia-response element (HRE), and controls the expression
of several genes involved in many aspects of cancer progression,
including angiogenesis, metabolic adaptation, apoptosis resistance,
invasion, and metastasis [21–23]. Many genetic alterations that
inactivate tumor suppressors or activate oncoproteins have been
involved in increasing the basal levels of HIF-1α in cancers, onto
which is superimposed the physiological response to hypoxia [24].
Our previous ﬁndings showing that HIPK2 knockdown induces
increased tumor growth in vivo [6], suggest that HIPK2 depletion in
tumor cells might activatemore than one survival pathway that, in the
presence of HIPK2, is negatively regulated. Therefore, the aim of this
studywas to evaluate the effect of HIPK2 on themodulation of HIF-1α/
VEGF pathway and themolecularmechanisms underlying this activity.
2. Materials and methods
2.1. Cell culture and treatments
H1299, RKO, and MCF7 cells were maintained in RPMI-1640
(GIBCO-Invitrogen) supplemented with 10% fetal bovine serum (FBS,
GIBCO, Invitrogen), antibiotics, and glutamine in humidiﬁed atmo-
sphere with 5% CO2 at 37 °C. The engineered siRNA control (siRNA C)
and HIPK2i RKO colon cancer cells were generated by stable
transduction of pSUPER vectors carrying HIPK2 or aspeciﬁc RNA-
interfering sequences [25] and selected as polyclonal populations; the
stable HIPK2 interfered H1299 lung cancer cell line (H1299-HIPK2i),
generated as above, was a kind gift from S. Soddu (Regina Elena Cancer
Institute, Rome Italy) [10]. The engineered breast cancer MCF7-HIPK2i
cell line was generated by infection with LV-THMsi/HIPK2 recombi-
nant lentivirus (see below).
The H1299 HIPK2-inducible (H1299-HIPK2-IND) cell line has been
previously described [26]. To induce HIPK2 expression, Ponasterone A
(PonA) (Alexis Biochemicals, San Diego, CA) was added to the medium
of H1299-HIPK2-IND cell line to a ﬁnal concentration of 2.5 μM for 8 h
unless otherwise speciﬁed. The transcriptional induction of HIPK2, in
two different inducible clones, was determined by RT-PCR analysis.
For DNA damage, subconﬂuent cells were treated with adriamycin
(ADR)diluted into themediumtoaﬁnal concentrationof 2 μg/ml for 18h.
2.2. Lentivirus-vector construction
The human immunodeﬁciency virus type 1-derived lentiviral
vector (designed LV-THM) [27] was used to generate constitutively
active pLV-THMsi/HIPK2 vector for HIPK2 depletion. Vector was
constructed by using standard cloning procedure. Brieﬂy, the H1-
shRNA-TTTTTcassettewas excised frompSUPER-HIPK2 vector [25] and
cloned in pLV-THM lentiviral vector (kindly provided by Dr. D. Trono,
University of Geneva, Switzerland), generating the new pLV-THMsi/
HIPK2 vector. The recombinant lentivirus was produced by transient
transfection of 293Tcells according to a standard protocol [28]. Brieﬂy,
20 μg of the pLV-THMsi/HIPK2 plasmid vector was co-transfected in
subconﬂuent 293T cells along with 15 μg of pAX2 and 6 μg of pMD2G-
VSVG (kindly provided by Dr. D. Trono, University of Geneva, Switzer-
land) by calciumphosphate precipitation. After 6–8 h cell mediumwas
replaced with fresh medium supplemented with 1.0 mM sodium
pyruvate (GIBCO-BRL). Lentiviruses were harvested 48 h later,
centrifuged 5min at 3,000 RPM, and stored at −80 °C. Lentiviral stocks
were titered following standard protocols, and routinely a viral titer of
106 transducing units per ml (TU/ml) was achieved.
For RNA interference, MCF7 cells were seeded in 24-well plate
(104/well) and infected with LV-THMsi/HIPK2 recombinant lentivirus
(at m.o.i. of 10 TU/cell) supplemented with 8.0 mg/ml of polybrene
reagent (Sigma). Sixteen hours later, cells were washed andreplenished with fresh medium. HIPK2 interference was checked by
RT-PCR one week after infection and the interfered cells were kept in
culture for at least 3 months to perform the experiments. A non-
speciﬁc target sequence was used to generate control interference
(siRNA C). At least three different recombinant lentivirus infections
were performed with comparable results.
2.3. RNA extraction and reverse trancriptase (RT)-PCR
Cells and tumors were harvested in TRIzol Reagent (Invitrogen)
and total RNA was isolated following the manufacturer's instructions.
The ﬁrst strand cDNA was synthesized according to the manufac-
turer's instructions (Moloney murine leukemia virus reverse tran-
scriptase kit, Applied). Semi-quantitative RT-PCR was carried out by
using HOT-MASTER Taq (Eppendorf) with 2 μl cDNA reaction and
genes speciﬁc oligonucleotides under conditions of linear ampliﬁca-
tion. The sequence of the primers used for RT-PCR was as follows:
HIF-1α forward: 5′-CAGAAGATACAAGTAGCCTC-3′;
HIF-1α reverse: 5′-CTGCTGGAATACTGTAACTG-3′;
VEGF forward: 5′-CCTGGTGGACATCTTCCAGGAGTA-3′;
VEGF reverse: 5′-TCACCGCCTCGGCTTGTCACA-3′.
Human VEGF monomers exists as ﬁve different isoforms of 121, 145,
165, and 206 amino acids that are produced by alternative splicing
from a single gene containing eight exons [29] and VEGF 121 and 165
appear to be the most abundant of the isoforms. Therefore, the
primers for VEGF RT-PCR analysis were designed to mostly detect
those two isoforms, as reported [30]. The primers for HIPK2 and
GAPDH have been described previously [25]. PCR was performed in
duplicate in three different experiments. PCR products were run on a
2% agarose gel and visualized with ethidium bromide. The house-
keeping GAPDH mRNA was used as internal standard and ampliﬁed
from the same cDNA reaction mixture. Densitometric analyses were
applied to quantify mRNA levels.
2.4. Western blot analysis
Total cell extracts (for HIPK2, VEGF, and Flag detection) were
prepared by incubating at 4 °C for 30 min in lysis buffer (50 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 150 mM KCl, 1 mM
dithiothreitol, 1% Nonidet P-40) plus a mix of protease and
phosphatase inhibitors (Sigma Chemical Company, MO, USA). Nuclear
extracts (for HIF-1α detection) were prepared essentially as described
[31]. Proteins were then separated by SDS-PAGE and blotted onto
nitrocellulose (BioRad, CA, USA). The membranes were probed with a
primary antibody followed by with horseradish-peroxidase conju-
gated secondary antibody. The antibodies used were: mouse mono-
clonal anti-HIF-1α (Novus Biologicals, UCS Diagnostic, Italy), mouse
monoclonal anti-Flag (Sigma, Saint Louis, USA), rabbit antiserum anti-
HIPK2 [9] (kindly provided by M.L. Schmitz, Justus-Liebig-University,
Giessen, Germany), rabbit polyclonal anti-VEGF (Santa Cruz), mouse
monoclonal anti-tubulin (Immunological Sciences), andmousemono-
clonal anti-Hsp70 (Stressgene, BC, Canada). Immunoreactivity was
detected with the Advanced-ECL chemoluminescence reaction kit
(Amersham., IL, USA).
2.5. Chromatin immunoprecipitation (ChIP) and Re-ChIP assays
ChIP analysis was carried out essentially as described [26]. Brieﬂy,
cells were crosslinked with 1% formaldehyde for 10 min at room
temperature and formaldehyde was then inactivated by the addition
of 125 mM glycine. Chromatin extracts containing DNA fragments
with an average size of 500 bp were incubated overnight at 4 °C with
milk shaking using rabbit polyclonal anti-HIPK2 (Santa Cruz), rabbit
antiserum anti-PAN-acetylated Histone H4 (ac-H4, Upstate
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(HDAC1, Sigma), and mouse monoclonal anti-Flag (Sigma) antibodies.
Before use, protein G (Pierce) was blockedwith 1 μg/μl sheared herring
sperm DNA and 1 μg/μl BSA for 3 h at 4 °C and then incubated with
chromatin and antibodies for 2 h at 4 °C. In Re-ChIP experiments,
complexes were eluted by incubation for 30 min at 37 °C in 25 μl
10mMDTT. After centrifugation, the supernatantwas diluted 20 times
with Re-ChIP buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris–HCl pH 8.1) and subjected again to the ChIP procedure.
PCR was performed with HOT-MASTER Taq (Eppendorf) using 2 μl of
immunoprecipitated DNA and promoter-speciﬁc primers for human
HIF-1α promoter [32,33] that were as follow: HIF-1α-prom forward
(−306/−286): 5′-tctttcctccgccgctaaaca-3′; HIF-1α-prom reverse (+14/
−9): 5′-agacgaggcagcactgtgcact-3′, ﬂanking a region between nucleo-
tide −306 and +14 of the HIF-1α promoter region (location based on
nucleotide upstream of HIF-1α start codon).
Immunoprecipitation with non-speciﬁc immunoglobulins (No Ab)
was performed as negative controls. PCR products were run on a 2%
agarose gel and visualized with ethidium bromide.
2.6. Transfection, plasmids, and transactivation assay
Transient transfection was carried out using the N,N-bis-(2-
hydroxyethyl)-2-amino-ethanesulphonic acid-buffered saline (BBS)
version of the calcium phosphate procedure [34]. The amount of
plasmid DNA in each sample was equalized by supplementing with
empty vector. The transfection efﬁciency was assayed by the use of a
ﬂuorescent microscope, after co-transfecting with a GFP-vector. The
expression vectors used in this study were: wild-type Flag-HIPK2, its
kinase defective Flag-K221R mutant [8], Flag-HIPK2ΔC and Flag-
HIPK2-ΔN deletion mutants [9] (kindly provided by T.G. Hofmann,
German Cancer Research Center, Heidelberg, Germany), and the
dominant negative form of HIF-1α without DNA binding domain and
transactivation domain (pCEP4-HIF-1αDN) [35] (kindly provided by B.
H. Jiang, Nanjing Medical University, China).
For transactivation assay, cells were plated in 60 mm dishes and
transiently transfected with the VEGF-luc promoter reporter and a
VEGF deletion mutant in the HIF binding site (VEGF-mut-luc) [36]
(kindly provided by C. Gaetano, IDI, IRCCS, Rome, Italy), HIF-1α-
pH800 (−541/+284), and the deletion mutant HIF-1α-p9F (−105/
+284), HIF-1α-p19E (−94/+284), HIF-1α-p8D (−41/+284), HIF-1α-
p15C (−30/+284), and HIF-1α-p1A (+217/+284) luciferase reporter
constructs [33]. Thirty-six hours after transfection luciferase activity
was assayed. Trichostatin A (Sigma) was added to culture medium at
100 nM for 18 h before luciferase activity was assayed. Transfection
efﬁciency was normalized with the use of a co-transfected pCMV β-
galactosidase plasmid (β-gal). Luciferase activity was assayed on
whole cell extract and the luciferase values were normalized to β-gal
activity and protein content. At least three independent experiments
were performed in duplicate.
2.7. Morphogenesis assay on Matrigel
Conditionedmedia (CM)werepreparedby incubating subconﬂuent
C-RKO and RKO-HIPK2i cells in serum-free medium for 24 h. Media
were then harvested and concentrated 10 times by ultraﬁltration using
Vivapure IEX spin columns (Sartorius, Italy) at 4 °C and stored at −20 °C
until use. Endothelial cell differentiation by using the in vitroMatrigel
assay was performed as previously described [30]. Brieﬂy, a 48-
microwell plate was ﬁlled with 100 μl/well of unpolymerized Matrigel
(9.8 mg/ml, BD Biosciences, USA) and allowed to polymerize for 1 h at
room temperature under air ﬂow. Human umbilical vein endothelial
cells (HUVEC) (104 cells/well) were plated into wells containing
endothelial cell growth medium (ECGM, Promo Cell, Germany) with
Supplement mix plus 8% fetal calf serum (FCS), C-RKO (siRNA control)
and RKO-HIPK2i cell-conditioned media, and cultured for 18 h at 37 °Cin a 5% CO2 humidiﬁed atmosphere. Experiments were performed at
least three times with three different interfered cell populations. Cell
growth and bidimensional organization (tube formation) were
observed by a Leitz DM-IRB inverted microscope (Leica, Germany)
and images were captured using a connected Canon Powershot G6
digital camera and saved as TIFF ﬁles. Image analysis of the cell pattern
was carried out using the QWin image analysis software, as previously
detailed [37], and the following parameters were estimated: area (%)
covered by endothelial cells (EC), total length (mm) of EC network per
ﬁeld, and number of meshes and branching points per ﬁeld. Numbers
are the mean of three independent experiments.
2.8. Histologic analysis of blood vessel density in tumor xenografts
Six-week-old CD-1 nude (nu/nu) mice (Charles River Laboratories,
Calco, Italy) were used for in vivo studies, as previously described [6].
Each experimental group included eight animals and experiments
were performed in accordance with institutional standard guidelines
for animal experiments. Solid tumorswereobtainedby injecting3×106
viable C-RKO and RKO-HIPK2i cells suspended in 0.2 ml PBS into the
mice right-ﬂank muscle (i.m.). C-RKO and RKO-HIPK2i tumor xeno-
grafts were explanted after threeweeks post-injection, frozen in liquid
nitrogen or parafﬁn embedded, sectioned, and stained with hematox-
ylin and eosin. Sections, 5 μm thick, were obtained from tissue blocks
for the immunohistochemical visualization of thevessels present in the
tumors. The sections were pre-treated with 2% normal goat serum, 1%
BSA, 0.1% Tween 20 in PBS pH 7.4 at room temperature for 20min, and
then incubated overnight at 4°C in humidiﬁed chambers with rabbit
anti-human Von Willebrand factor (vWf, Sigma, Saint Louis, USA)
antibody. After repeatedwashingwith PBS the sectionswere incubated
with HRP-conjugated anti-rabbit secondary antibody (ImmPress,
Vector Laboratories Inc., Burlingame, CA) for 30 min at room
temperature. After rinsing in PBS, 3,3′-diaminobenzidine tetrachloride
was applied to visualize the reactionproduct. To verify the speciﬁcity of
the immunostaining some sample were similarly processed omitting
the primaryantibodyaswell as using primaryantibodies pre-adsorbed
with antigen excess. From each sample 3 random selected sections,
from at least three different tumors, were used for themorphometrical
analysis. They were examined under a light microscope (Leica DMR,
Leica Microsystems, Wetzlar, Germany) at a primary magniﬁcation of
×10 in order to select the three areas with the highest degree of
vascularization (hot spots), free of necrosis or haemorrhage. The
images of the hot spots were recorded using a digital camera (DC200,
Leica Microsystems, Wetzlar, Germany) and saved as TIFF ﬁles. Image
analysis was performed by using QWin image analysis software to
evaluate the percent area covered by immunostained structures as
previously described [37]. Data obtained from each specimen were
averaged toprovide a representative value for that specimen. Statistical
comparisons between the experimental groups were tested by one-
way analysis of variance (ANOVA). pb0.05 was always considered as
the limit for statistical signiﬁcance.
2.9. Statistical analyses
Continuous variables were analysed by the Student t test or 1-way
ANOVA, along with Dunnet's test when appropriate. Data are
expressed as mean±SD. A value of p≤0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Effect of HIPK2 on HIF-1α gene expression
In the attempt to investigate the role of HIPK2 in HIF-1α gene
regulation, we ﬁrst determined the mRNA levels of HIF-1α in RKO and
MCF7 cell lines stable interfered for HIPK2 function (HIPK2i),
Fig. 1. Effect of HIPK2 on HIF-1 α gene expression. (A) HIF-1α expressionwas determined in RKO and MCF7 cells, stable interfered for HIPK2 function (HIPK2i), compared to the non-
target RNA-interference cells (siRNA C), by reverse transcriptase-PCR (RT-PCR). GAPDH was used as loading control. One representative experiment from three independent
experiments was shown. (B) RKO and MCF7 cells interfered as in (A) were treated with ADR for 18 h and HIPK2 expression (indicated by arrow) was assessed by Western
immunoblotting. Anti-tubulin was used as protein loading control. A.s.: aspeciﬁc signal. (C) Western immunoblotting of HIF-1α protein levels in RKO and MCF7 cells interfered as in
(A). Anti-hsp70 was used as protein loading control. (D) Two different clones (cl.1, cl.2) of H1299-HIPK2-IND cells were treated with PonA for 8 h, to induce HIPK2 expression, before
harvesting for RT-PCR analysis. The HIPK2 and HIF-1αmRNA levels were shown. GAPDH was used as loading control. (E) Densitometric analysis of HIF-1α and HIPK2 levels as in (D)
was performed and normalized values to GAPDHmRNA levels were plotted. The bars represent the mean relative ratio HIF-1α/GAPDH and HIPK2/GAPDH (indicated as fold of mRNA
expression)±S.D. of duplicate samples of three independent experiments. ⁎p0.0033 comparedwith control cells without PonA treatment. (F, RNA panel) H1299 cells were transfected
with Flag-empty, HIPK2-Flag and K221R-Flag mutant expression vectors. Thirty-six hours post-transfection cells were harvested and HIF-1α expression was determined by RT-PCR
analysis. GAPDH was used as loading control. One representative experiment from three independent experiments was shown. (F, protein panel) The ectopic expression of HIPK2
protein was shown by anti-Flag Western immunoblotting. L.c.: loading control.
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PCR analyses. As shown in Fig. 1A, HIPK2 mRNA levels reduced after
speciﬁc RNA-interference (HIPK2i) as expected, compared to the
siRNA C cells, while the expression of HIF-1α mRNA levels were
signiﬁcantly (pb0.001) induced in both cell lines, compared to the
siRNA C cells. Comparable results were obtained in three different
HIPK2-interfered cell populations, following densitometric analysis of
PCR products. The efﬁciency of HIPK2 downmodulation in the siRNA
systems was also evaluated at protein level. It is known that HIPK2 is
an unstable protein barely detected at basal level [38,39], hence it is
quite difﬁcult to show HIPK2 protein levels unless stabilized upon
DNA damage [i.e., Ref. [25]]. Therefore, Western immunoblotting of
RKO and MCF7 cells lines, transfected with siRNA C and siRNA-HIPK2
(HIPK2i) vectors, was performed after ADR (2 μg/ml) treatment for
18 h. As shown in Fig. 1B, HIPK2was induced only in siRNA C cells after
ADR treatment, while the HIPH2 depleted cells lost this induction,
indicating the good efﬁciency of HIPK2 depletion by siRNA. Similarly,
HIF-1αwas evaluated at protein level. As shown in Fig. 1C, HIF-1αwas
induced in both RKO and MCF7 cell lines after HIPK2 depletion
(HIPK2i), compared to the siRNA control cells (siRNA C).
Next, to further analyse the involvement of HIPK2 in regulating
HIF-1α expression, we took advantage of the H1299-HIPK2-IND cellline carrying transcriptionally inducible HIPK2 protein after PonA
treatment, previously generated by us [26]. HIF-1αmRNA levels were
evaluated by RT-PCR in two different PonA-inducible clones. Average
expression levels of HIPK2 after PonA treatment were shown in Fig.
1D; concomitantly to HIPK2 upregulation, HIF-1α drop off was
signiﬁcantly (p0.0033) assessed when cells were treated with PonA
(Fig. 1D), as also evaluated after densitometric analysis of PCR
products (Fig. 1E). To conﬁrm these ﬁndings also after DNA transient
transfection H1299 cells were transfected with HIPK2-Flag and
K221R-Flag kinase-defective expression vectors. As shown in Fig. 1F
(RNA panel), HIF-1α mRNA expression levels were signiﬁcantly
reduced (pb0.001) by HIPK2 but not by K221Rmutant overexpression.
The ectopic expression of HIPK2 was shown as anti-Flag immunoblot-
ting (Fig. 1F, protein panel). Altogether, these ﬁndings suggest that
HIPK2 negatively regulated HIF-1α gene expression and that HIPK2
catalytic activity was involved in this regulation.
3.2. HIPK2 was recruited onto HIF-1α promoter and repressed promoter
activity
We asked whether HIPK2 could be recruited in vivo onto HIF-1α
promoter and which part of the protein allowed attachment to this
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precipitation (ChIP) assays. MCF7 cells were either transfected with
HIPK2-Flag, HIPK2ΔC and HIPK2ΔN deletion mutant expression
vectors, or with the Flag-empty vector. Chromatin complexes were
immunoprecipitated with anti-Flag antibody and PCR analysis was
performed using speciﬁc primers ﬂanking the human HIF-1α
promoter [32]. As shown in Fig. 2A (left panel), HIPK2 as well as the
HIPK2-N-terminus deletion mutant were both efﬁciently recruitedonto HIF-1α promoter while the HIPK2-C-terminus deletion mutant
lost this activity. As a control of HIPK2-Flag binding speciﬁcity to the
HIF-1α promoter, we used speciﬁc primers spanning the human
GAPDH promoter region. As expected (Fig. 2A, right panel), no GAPDH
ampliﬁcation was observed after chromatin immunoprecipitation
with anti-Flag, antibody while a clear PCR band was detected using
the genomic DNA as template. The ectopic expression of HIPK2-Flag
and its mutants was shown as anti-Flag immunoblotting (Fig. 2B).
Next, endogenous HIPK2 recruitment onto HIF-1α promoter, as
well as chromatin remodeling, was tested in MCF7 cells stable
interfered for HIPK2 function (HIPK2i), compared to the non-target
RNA-interference cells (siRNA C), by ChIP and Re-ChIP technique (see
Materials and methods for details). Chromatin complexes were
immunoprecipitated with anti-HIPK2, anti-PAN-acetylated Histone
H4 (ac-H4), and anti-Histone deacetylase 1 (HDAC1) antibodies and
PCR analysis was performed using speciﬁc primers ﬂanking the human
HIF-1αpromoter [32]. As shown in Fig. 2C (ChIP, left panel), bothHIPK2
and HDAC1 were recruited onto HIF-1α promoter in siRNA control
(siRNA C) cells, while this recruitment was strongly impaired after
HIPK2 depletion (HIPK2i). Conversely, silencing of endogenous HIPK2
resulted in strong increase of the ac-H4 levels, suggesting an open
chromatin structure of this promoter as also evidenced by reduction of
HDAC1 levels on HIF-1α promoter (Fig. 2C, ChIP, left panel). We and
other have previously shown, by ChIP analysis, that HDAC1 can be
recruited with HIPK2 in co-repressor complex [2,6]. Re-ChIP experi-
ments offer an ideal means to test whether HIPK2 and HDAC1 are co-
recruited onto HIF-1α promoter. After we performed ReChIP analysis
immunoprecipitating the HDAC1-containing complexes with an anti-
body against HIPK2 (or immunoprecipitating HIPK2-containing com-
plexes with an antibody against HDAC1), only those DNA sequences
that are simultaneously bound by both proteins would be ampliﬁed in
the sequent PCR. As shown in Fig. 2C (Re-ChIP, right panel), HIPK2 and
HDAC1 are co-recruited on the same DNA fragments suggesting that
the two factors co-occupy common target loci. The HDAC1 (or HIPK2)
ReChIP signals were not due to a non speciﬁc background, since when
the DNA–protein complexes were subjected to a second immunopre-
cipitationwithout antibody, no DNAwas immunoprecipitated (Fig. 2C,
ReChIP, right panel, No Ab). Similar results were obtained in RKO cells
(data not shown). The ChIP experiments were repeated at least twice
with comparable results. Altogether, these results support a role for
HIPK2 inHIF-1αpromoter silencing through its co-recruitmentwith, at
least, HDAC1. They also suggest that the HIPK2 C-terminus region, a
region important for many protein interactions [i.e., Refs. [3,7]], is also
involved in HIF-1α promoter binding.
Next we evaluated whether HIPK2 could regulate the HIF-1α
promoter activity. To this aim, we co-transfected the HIF-1α-pH800-
luc (−538 to +284) reporter construct, encoding the HIF-1α promoter
[33] with HIPK2, K221R kinase defective, HIPK2ΔC and HIPK2ΔNFig. 2. HIPK2 binding on HIF-1α promoter activity and chromatin remodeling. (A) ChIP
experiments were performed with anti-Flag antibody on MCF7 cells transfected with
HIPK2-Flag, HIPK2ΔC and HIPK2ΔN deletion mutant expression vectors, and with Flag-
empty expression vector. PCR analyses were performed on the immunoprecipitated
DNA samples using speciﬁc primers for the human HIF1-α promoter. A sample
representing linear ampliﬁcation of the total input chromatin (Input) was included as
control. Additional controls included immunoprecipitation performed with non-
speciﬁc immunoglobulins (No Ab). A representative experiment of three independent
experiments was shown. Ampliﬁcation of GAPDH promoter (right panel) was used as
control of HIPK2 binding speciﬁcity to the HIF1-α promoter. Schematic representation
of the HIPK2 expression vectors was shown. (B) The ectopic expression of HIPK2 protein
(as indicated by arrows) was shown by anti-FlagWestern immunoblotting. (C) ChIP and
Re-ChIP experiments (see Materials and methods) were performed with anti-HIPK2,
anti-HDAC1, and anti-ac-H4 antibodies on MCF7 cells depleted of HIPK2 function
(HIPK2i) compared to the siRNA control (siRNA C) cells. ReChIP analysis was performed
using HDAC1+HIPK2 or HIPK2+HDAC1 antibodies, as indicated. PCR analyses were
performed on the immunoprecipitated DNA samples using speciﬁc primers for the
human HIF1-α promoter. A sample representing linear ampliﬁcation of the total input
chromatin (Input) was included as control. Additional controls included immunopre-
cipitation performed with non-speciﬁc immunoglobulins (No Ab).
Fig. 3. Effect of HIPK2 on HIF1-α promoter activity. (A) H1299 cells were co-transfected with the HIF1-α-p800 reporter construct (see Materials and methods) together with HIPK2,
K221R mutant, HIPK2ΔC and HIPK2ΔN deletion mutant expression vectors. Luciferase activity was measured 36 h after-transfection. Results, normalized to β-galactosidase activity,
are representative of three independent experiments performed in duplicate, ±S.D. RLU: Relative Luciferase Units. ⁎pb0.0001 compared with both control and K221R transfected
cells and deletion mutants. (B) H1299 cells depleted of HIPK2 function (HIPK2i) or siRNA control (siRNA C) were transfected with HIF1-α-p800 reporter construct luciferase activity
was measured 36 h after-transfection. Results, normalized to β-galactosidase activity, are representative of three independent experiments performed in duplicate, ±S.D, and are
presented as fold of induction of luciferase activity. ⁎pb0.0001 compared with siRNA control. (C) H1299 cells were co-transfected with HIPK2 and K221R kinase defective mutant
along with different smaller HIF-1α-luc promoter fragment. Luciferase activity was measured 36 h after-transfection. Results, normalized to β-galactosidase activity, are
representative of three independent experiments performed in duplicate, ±S.D. R.L.U.: Relative Luciferase Units. ⁎pb0.0001 compared with both control and K221R transfected cells.
(Lower panel) Schematic representation of HIF-1α-luc promoter fragments and HIPK2 repression is shown. (D) H1299 cells were co-transfected with HIPK2 and p15C reporter vector
in the presence or absence of TSA treatment (100 nM for 18 h). Results, normalized to β-galactosidase activity, are representative of three independent experiments performed in
duplicate, ±S.D. R.L.U.: Relative Luciferase Units.
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signiﬁcantly reduced the HIF-1α-pH800 promoter activity while the
K221Rmutant, as well as the HIPK2ΔN and HIPK2ΔC deletionmutants
failed to do so. The HIPK2 involvement in HIF-1α promoter repression
was also tested in H1299 cells depleted of HIPK2 function. As shown in
Fig. 3B, HIPK2 depletion signiﬁcantly induced HIF-1α-luciferase
activity, compared to the siRNA control (siRNA C) cells.
Next, we analysed, by luciferase assay, the HIPK2 capacity to
repress smaller fragments of HIF-1α promoter. As shown in Fig. 3C,HIPK2 efﬁciently inhibited the luciferase activities of almost all
mutants tested (spanning from −530 to +284). Interestingly, HIPK2
was not able to inhibit the luciferase activity of p1A reporter (spanning
from +217 to +284), suggesting that this might be the region
responsible of promoter repression by HIPK2. It has been recently
found that there is an active NFkB binding site at the position +150 to
+158 of the HIF-1α promoter [40] that might be involved in this
regulation. Finally, we performed a luciferase assay after co-transfect-
ing HIPK2 and HIF-1α-pH800-luc reporter in the presence or absence
Fig. 4. Effect of HIPK2 on HIF-1α-induced VEGF transcription. (A, RNA panel) VEGF expression was determined in RKO and MCF7 cells, stable interfered for HIPK2 function (HIPK2i),
compared to the non-target RNA-interference cells (siRNA C), by reverse transcriptase-PCR (RT-PCR), as in Fig.1A. GAPDHwas used as loading control. One representative experiment
from three independent experiments was shown. (Protein panel) Western immunoblotting of VEGF protein levels in RKO and MCF7 cells interfered as above. Anti-actin was used as
protein loading control. (B) H1299 stable depleted of HIPK2 function by RNA interference (HIPK2i) and the siRNA C cells were transfected with wild-type VEGF-luc reporter construct
or VEGF-mut-luc (deleted in the HIF-1α binding site) and 36 h after transfection assayed for luciferase activity, normalized by β-galactosidase activity. Data represent mean±S.D. of
three independent experiments performed in duplicate. RLU: Relative Luciferase Units. ⁎pb0.001 comparedwith siRNA C cells. (C) H1299-HIPK2-INDwere transfectedwith VEGF-luc
reporter construct and 24 h after transfection treated with PonA (to induce HIPK2 expression) for 12 h, before harvesting for luciferase activity, normalized by β-galactosidase activity.
Data represent mean±S.D. of three independent experiments performed in duplicate. RLU: Relative Luciferase Units. ⁎pb0.001 compared with control cells without PonA treatment.
(D) H1299 cells were co-transfected with VEGF-luc reporter or (E) VEGF-mut-luc (deleted in the HIF-1α binding site) and HIPK2-Flag or K221R-Flag mutant expression vectors and
36 h after transfection assayed for luciferase activity, normalized by β-galactosidase activity. Data represent mean±S.D. of three independent experiments performed in duplicate.
RLU: Relative Luciferase Units. ⁎p0.0013 compared with both Flag and K221R transfected cells. (F) H1299 cells stable depleted of HIPK2 function (HIPK2i) were co-transfected with
VEGF-luc reporter (2 μg) and increasing amount (0, 1, 2, 4 μg) of HIF-1α dominant negative construct (HIF-1αDN). The amount of plasmid DNA in each sample was equalized by
supplementing with empty plasmid. Luciferase activity was assayed 36 h after transfection and normalized by β-galactosidase activity. Data represent mean±S.D. of three
independent experiments performed in duplicate. ⁎pb0.001 compared with VEGF-luc control without HIF-1αDN co-transfection.
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in Fig. 3D, TSA treatment inhibited the HIPK2-induced repression of
HIF-1α promoter.
3.3. Effect of HIPK2 on HIF-1α-dependent VEGF transcription
To evaluate the involvement of HIPK2 in HIF-1α-mediated VEGF
transcription VEGF mRNA levels were ﬁrst analysed in RKO and MCF7
cells interfered for HIPK2 function, as in Fig. 1A. As shown in Fig. 4A
(RNA panel), the expression of VEGF mRNA levels were signiﬁcantly(pb0.001) induced in both cell lines following HIPK2 knockdown.
Comparable results were obtained in three different HIPK2-interfered
cell populations, following densitometric analysis of PCR products.
VEGF was also evaluated at protein level byWestern immunoblotting.
As shown in Fig. 4A (protein panel), VEGF levels were induced in both
RKO and MCF7 cell lines after HIPK2 depletion (HIPK2i), compared to
the siRNA control cells (siRNA C). Next, regulation of VEGF transcrip-
tion was evaluated by luciferase assay. To this end, H1299 cells
interfered for HIPK2 function (HIPK2i) and the corresponding siRNA
control cells (siRNA C) were transfected with VEGF-luciferase reporter
Fig. 5. HIPK2 knockdown enhances in vitro tube formation of human umbilical vein
endothelial cells (HUVEC) seeded on Matrigel. Conditioned media (CM) were collected
from RKO HIPK2-interfered (HIPK2i) and siRNA control (siRNA C) cells to treat HUVEC
for 18 h. (A) Phase contrast images of the capillary-like patterns formed byHUVEC in the
presence of siRNA C (central panel) and HIPK2i (lower panel) cells CM; the upper panel
represents the capillary-like patterns formed by HUVEC cultured in endothelial cell
growth medium (ECGM), as positive control (Pos. Ctr) (×5). (B) Morphometric
characterization of the patterns generated by HUVEC on Matrigel, as in (A). Data
represent the dimensional (upper plot, showing the area — % and length — mm/ﬁeld)
and topological (lower plot, showing the branching and meshes — number/ﬁeld)
parameters. Data represent mean (±standard error) of three independent experiments.
⁎pb0.05; ⁎⁎pb0.01 (one-way ANOVA, followed by Dunnet's test for multiple
comparisons compared with non-target RNA interference group).
Fig. 6. Effect of HIPK2 knockdown on tumor vascularity. (A) Histological analysis of
blood vessels in RKO HIPK2 interfered (HIPK2i, right panel) and siRNA control (siRNA C,
left panel) tumor xenografts by staining with hematoxylin/eosin and immunoperox-
idase detection of endothelial cells using an anti-vWF antibody (×10). (B) Quantiﬁcation
of blood vessels density in HIPK2i and siRNA C tumor xenografts. The data represent the
mean (±standard error) of the frequency of vessels hits among 300 random sampling
points from three different tumors of either genotype (expressed as percent ﬁeld area
covered by the immunoreactivity). ⁎pb0.01 (two-samples Student's t-test) compared
with C-RKO tumors. (C) HIF-1α and VEGF expression was determined in two different
RKO HIPK2 interfered (HIPK2i) and siRNA control (siRNA C) tumor xenografts, by
reverse transcriptase-PCR (RT-PCR). GAPDH was used as loading control.
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the VEGF-mutant-luciferase reporter (VEGF-mut-luc), mutated in the
HIF binding site [36] and 36 h after transfection assayed for luciferase
activity. The results obtained show that the VEGF-luciferase activity
was signiﬁcantly induced following HIPK2 knockdown (HIPK2i),
compared to the non-target RNA-interference (siRNA C) (Fig. 3B);
also the VEGF-mut-luc reporter was induced by HIPK2 depletion,
although in a lesser extent compared to the wild-type reporter (Fig.
4B). In a comparable but opposite manner, VEGF-luciferase activity
was signiﬁcantly reduced following HIPK2 induction with PonA in
H1299-HIPK2-IND cells (Fig. 4C). In agreement with these ﬁndings,
HIPK2 overexpression in H1299 cells, signiﬁcantly reduced the VEGF
reporter activity, compared to the K221R mutant (Fig. 4D), suggesting
that the HIPK2 catalytic activity was involved in this regulation; also
the VEGF-mut-luc reporter was inhibited by HIPK2 depletion,
although in a lesser extent compared to the wild-type reporter (Fig.
4E) Finally, to demonstrate that HIF-1α is required for the induction of
VEGF following HIPK2 knockdown, H1299-HIPK2i cells were co-
transfected with VEGF reporter construct and increasing amounts of
HIF-1α dominant negative (HIF-1αDN) expression vector [35]. Fig. 4F
shows that the VEGF-luciferase activity was signiﬁcantly inhibited by
HIF-1αDN co-transfection, conﬁrming the role of HIF-1α, at least in
part, in VEGF transcriptional activation in our model of HIPK2i cells.
These ﬁndings suggest that HIPK2 regulated the HIF-1α-induced
transcription of VEGF in normoxic condition in tumor cells.
3.4. HIPK2 knockdown enhances in vitro tube formation and in vivo
tumor vascularity
To examine whether the effect of HIPK2 on the modulation of HIF-
1α/VEGF pathway was associated with endothelial cell morphogen-esis, the growth of human umbilical vein endothelial cells (HUVEC)
was evaluated in vitro on Matrigel in the presence of cell-conditioned
media (CM) of RKO cells depleted of HIPK2 function (HIPK2i) or
transfected with non-target RNA-interference (siRNA C). As shown in
Fig. 5A, the CM fromHIPK2 depleted cells provoked a positive effect on
the tube formation of HUVEC, compared with the CM from siRNA C
cells. The tube formation with the CM from HIPK2i cells was
comparable to that induced in the positive control (Pos. Ctr.,
endothelial cell growth medium – ECGM – treated cells) (Fig. 5A,
upper panel). Morphometric analysis of tube formation conﬁrmed
these ﬁndings. The capillary-like pattern formed by HUVEC grown in
the presence of HIPK2i cells CM exhibited a higher extension and
complexity when compared to HUVEC grown in the presence of siRNA
C cells CM, as demonstrated by the signiﬁcant (pb0.05, ANOVA and
Dunnet's test) increase of dimensional (area%, length) and topological
(branching points and number of meshes) parameters (Fig. 5B).
Finally, variations in tumor vascularity were evaluated by
immunohistochemical analysis of tumors established from RKO cells
depleted of HIPK2 function (HIPK2i) or transfected with siRNA control
vector (siRNA C) by using an anti-von Willebrand Factor (vWF)
antibody. As shown in Fig. 6A increased blood vessel density was
found in HIPK2i-derived tumors compared with their siRNA C
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methods) showed that HIPK2i tumors were characterized by 3-fold
increase (pb0.01) of the vWF-immunopositive vessel area compared
with non-target RNA interference counterparts (Fig. 6B). Finally,
mRNA expression of VEGF and HIF-1α levels were analysed in tumor
xenografts derived fromHIPK2 depleted and siRNA control cells by RT-
PCR analysis. As shown in Fig. 6C, VEGF and HIF-1αmRNA expression
levels were up-regulated in tumors derived fromHIPK2 depleted cells.
Altogether, these data suggest that, loss of HIPK2 function was
associated with tube formation in HUVEC and increased tumor
vascularity that correlated with HIF-1α and VEGF up-regulation.
4. Discussion
The results of our study showed that HIPK2 knockdown correlated
with increased tumor vascularity in vivo and tube formation of HUVEC
in vitro. We also showed for the ﬁrst time that HIPK2 was co-recruited
with HDAC1 onto HIF-1α promoter and that regulated HIF-1α at
transcriptional level, thus, HIPK2 knockdown increased HIF-1α gene
expression and HIF-1α-dependent VEGF transcription.
We have previously shown that HIPK2 silencing increases in vivo
tumor growth [6]; moreover, it has been recently shown in Hipk2 KO
mice, that, β-catenin activity is a target of HIPK2 transcriptional
repression, thus HIPK2 suppresses β-catenin-mediated activation of
cyclin D1, controlling cell proliferation and increasing the propensity
for tumorigenesis [13]. Among the β-catenin target genes is VEGF [41]
and we have recently shown that HIPK2 regulates the β-catenin-
induced VEGF expression in tumor cells [42]. Altogether, these
ﬁndings strongly support a role for HIPK2 in restraining tumor
progression, regulating cell growth and vascularity in tumor cells.
However, it has also been shown that Hipk1/Hipk2 double-homo-
zygous mutant embryos reveal severe defect in vessel formation [43],
showing a wide range of functions for HIPK2 during development and
tumorigenesis, likely trough interactions with different proteins.
Increasing evidence indicates that HIPK2 is able to modulate the
transcription activity of a growing number of transcription factors
through for instance phosphorylation mechanisms that can act on
chromatin-remodeling complexes by inﬂuencing the stability or the
localization of transcription factors and co-regulators and by modify-
ing protein–protein and (or) protein–DNA interactions [44]. The
molecular analysis of the HIPK2/HIF-1α regulation has allowed us to
provide further insights into the role of HIPK2 as transcriptional
repressor. Our ﬁndings showed, for the ﬁrst time, that HIPK2 was
recruited onto HIF-1α gene promoter and co-recruited, by Re-ChIP
experiments, with HDAC1 on the same DNA fragments suggesting that
the two factors co-occupy common target loci, likely regulating HIF-
1α transcriptional repression. This is supported by previous results
showing that a co-repressor complex between HIPK2 and HDAC1
leads to histone deacetylation and plays a critical role on the control of
gene transcription [2,6]. Thus, we showed here that HIPK2 depletion
was correlated with strong acetylation of the HIF-1α promoter as
assessed by ac-H4 binding to HIF-1α promoter. In agreement, HIPK2
overexpression strongly repressed the transcription of the HIF-1α-luc
promoter and consequently, of the HIF-1α-target gene VEGF. More-
over, TSA treatment impaired HIPK2 repression of HIF-1α-luc
promoter, suggesting a role for HDACs in HIPK2-mediated promoter
regulation. Interestingly, the HIPK2 inhibition of smaller HIF-1α-
promoter regions indicated the existence of important regulatory
elements in the HIF-1α promoter region spanning from +217 to +284,
suggesting that this might be the region responsible of promoter
repression by HIPK2. It has been recently found that there is an active
NFkB binding site at the position +150 to +158 of the HIF-1α promoter
[40] that might be involved in this regulation.
HIF-1α is mostly regulated at posttranscriptional levels by low
oxygen conditions [19]. As a novelty, our study showed that HIPK2
regulated HIF-1α at a transcriptional level independently of theoxygen context. To date, very fewworks have described a regulation of
HIF-1αmRNA [45–49]. In our work we identiﬁed HIPK2 as transcrip-
tion factor that was bound to and transcriptionally regulated HIF-1α
gene independently of the oxygen conditions. HIF-1α has a broad
impact on the expression of many genes involved in cell proliferation,
motility, and apoptosis [49]. In this regards we showed that
upregulation of both HIF-1α and its target gene VEGF took place in
HIPK2 depleted cells. By analysing HIPK2-interfered cells whose
endogenous HIF-1α activity was selectively inhibited by a dominant
negative vector [35], we veriﬁed that VEGF luciferase activity was
severely impaired, and thus partially depending on HIF-1α activity. In
agreement with these data, HIPK2 overexpression led to down-
regulation of both HIF-1α and VEGF mRNAs, compared to the K221R
kinase-defective HIPK2 mutant, suggesting that HIPK2 catalytic
activity was involved in this regulation. HIPK2 was also able to
slightly regulate the luciferase activity of a VEGF-luc reporter mutated
in HIF binding site. As reported above, VEGF can be regulated by many
different pathways and HIPK2 can take part in these regulations, as
also shown by our results [13,41,42].
Thus, together, these observations suggest that the stimulation of
HIF-1α expression by HIPK2 depletion could have a positive effect on
tumor development. Thus, HIF-1α has a special impact on cancer
progression because of its effect on angiogenesis [50]. Here, by
showing that HIPK2 is involved in the regulation of the HIF-1α/VEGF
pathway, it is tempting to speculate that loss of HIPK2 could constitute
a signal that tilts the balance toward survival and presumably
angiogenesis growth. In agreement with this hypothesis, our in vitro
and in vivo experiments showed that HIPK2 inactivation correlated
with increased tumor vascularity. It is known that the genetic
alterations that are responsible for tumor progression may underline
the ability of tumors to switch to an angiogenic phenotype. Since
HIPK2 can be deregulated in tumors by gene mutations, mRNA
downregulation, and protein cytoplasmic localization [6,11–14] lead-
ing to increased tumor growth, resistance to apoptosis, and p53
inhibition, it is reasonable to speculate that HIPK2 inhibition might
also predispose to tumor angiogenesis by HIF-1α de-repression,
among other mechanisms. However, further experiments are needed
to demonstrate the role of HIF-1α/VEGF pathway in the angiogenic
switch in HIPK2i-derived tumors.
The novel ﬁnding in this study is that HIPK2 regulated HIF-1α at a
transcriptional level repressing its mRNA and activity. The fact that
HIPK2 knockdown increased the expression of both HIF-1α and its
transcription target VEGF led us to hypothesize a role for HIPK2 in
controlling angiogenic switch through the HIF-1α/VEGF pathway.
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